MedPath

Magnesium sulfate

Generic Name
Magnesium sulfate
Brand Names
Concept Ob, Suflave, Suprep Bowel Prep Kit, Tis-U-sol
Drug Type
Small Molecule
Chemical Formula
MgO4S
CAS Number
7487-88-9
Unique Ingredient Identifier
ML30MJ2U7I
Background

A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)

Indication

Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.

Associated Conditions
Constipation, Convulsions, Hypomagnesemia, Torsades de Pointes, Barium poisoning, Severe Exacerbation of asthma
Associated Therapies
Bowel preparation therapy, Soaking aid for minor sprains and bruises
Clinical Trials
Related News

Erector Spinae Plane Block vs. Serratus Anterior Plane Block for Post-LSG Analgesia: A Randomized Trial

• A randomized clinical trial is underway to compare the efficacy of Erector Spinae Plane Block (ESB) versus Serratus Anterior Plane Block (SAPB) for pain management after Laparoscopic Sleeve Gastrectomy (LSG). • The study aims to assess the quality of recovery at 24 hours postoperatively using the QoR-15 score as the primary outcome measure. • Secondary outcomes include pain scores, opioid consumption, time to first analgesia, and incidence of postoperative nausea and vomiting. • The trial employs an opioid-sparing analgesic approach and involves 70 patients undergoing elective LSG surgery at Galway University Hospital.

Magnesium Sulfate Prevents Cerebral Palsy in Premature Babies: Cochrane Review

• A Cochrane review confirms that magnesium sulfate infusions given to women at risk of premature birth can prevent cerebral palsy in their babies. • The inexpensive treatment, costing approximately $6.50 per dose, has been recommended by the WHO since 2015 for women at risk of premature birth before 32 weeks. • A program in England demonstrated that widespread use of magnesium sulfate resulted in an estimated 385 fewer cases of cerebral palsy between 2018 and 2023. • Researchers call for increased global implementation and further studies to optimize the drug's administration, especially in low-resource settings.

Synbiotic Supplementation to Prevent Preterm Birth: A Multi-Center Trial

• A multi-center, randomized, placebo-controlled trial is underway to investigate the efficacy of synbiotic supplementation in preventing spontaneous preterm birth (sPTB). • Pregnant women at risk for sPTB between 80/7 and 106/7 weeks of gestation will receive either a synbiotic containing eight Lactobacillus strains or a placebo daily until delivery. • The primary outcome is gestational age at delivery, with secondary outcomes including PTB rates, PPROM rates, vaginal microbiome analysis, and neonatal outcomes. • The trial aims to recruit 402 participants across seven Belgian teaching hospitals over approximately 36 months to determine if synbiotics can prolong pregnancy and improve neonatal health.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy